Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

A Comparative Medicine Study by Penn Vet Identifies a New Approach to Combat Viral Infections

Published: Thursday, November 15, 2012
Last Updated: Thursday, November 15, 2012
Bookmark and Share
When a virus such as influenza invades our bodies, interferon proteins are among the first immune molecules produced to fight off the attack.

Interferon can also play a role in suppressing tumor growth and the effects of autoimmune diseases, and doctors may use an artificial form of interferon to treat patients with certain cancers or multiple sclerosis. But even this approach sometimes fails when patients’ bodies reject the foreign interferon or growing resistant to its effects.

A study by scientists from the University of Pennsylvania School of Veterinary Medicine offers a new strategy for enhancing the effects of interferon in fighting off infection. The research suggests that, by targeting a particular molecule in the interferon signaling pathway, specially designed drugs may be able to boost the activity of a person’s own interferon, augmenting the immune system’s fight against viruses. It’s possible that the same drugs might also be effective against some types of cancer and certain autoimmune conditions.

Serge Fuchs, a professor of cell biology in Penn Vet’s Department of Animal Biology and director of the School’s Mari Lowe Comparative Oncology Center, was the senior author on the paper published in the Proceedings of the National Academy of Sciences.

“The practical significance of our study is a demonstration of the ability to use emerging pharmaceuticals to reactivate an individual’s own interferon or to use a reduced dose to get the same effect,” Fuchs said.

Christopher Carbone and Hui Zheng of the Department of Animal Biology and John Lewis and Alexander Reiter of the Department of Clinical Studies played leading roles in the study. Additional Penn Vet collaborators were Sabyasachi Bhattacharya, Paula Henthorn and Kendra Bence. Zhong-Yin Zhang of Indiana University School of Medicine and Darren Baker of Biogen Idec also contributed.

The research would have been impossible without the team’s comparative-medicine approach, in which they examined the effects of activating the interferon pathway in both human cells and in cats affected by a naturally occurring disease. Mice would normally be the model organism of choice for such a study, but they lack a molecular element of the interferon pathway that humans and cats share.
“Mice are very convenient, but they may not always recapitulate human diseases that well,” Fuchs said. “Veterinary diseases happen naturally, and they provide a less convenient but a more truthful recapitulation of the human situation.”

Interferon fights viruses by binding to an interferon receptor on cells, triggering a cascade of other molecular events and leading to the production of proteins that prevent viruses from reproducing or that stimulate other immune responses. But because too much interferon can harm the host’s body, this signaling cascade has a built-in brake: Using a separate molecular pathway, interferon triggers the body’s cells to remove its own receptor, so the immune system attack doesn’t go on indefinitely.
“It’s very important to understand what regulates the responsiveness of cells to interferon, and a major factor is the levels of cell-surface receptors,” Fuchs said.

Although the researchers’ investigations of these pathways led them to identify a target for improving the body’s virus-fighting ability, they didn’t set out to discover a drug. Rather, they were attempting to solve a paradox of cell biology.

The paradox rests on the fact that many steps in the interferon-signaling pathway involve adding a molecule of phosphate to proteins in the cascade. Interferon itself promotes the addition of phosphate onto the interferon receptor, yet previous evidence suggested that the receptor resisted being removed by the cell if it had phosphate added. Given that interferon does in fact trigger the removal of its own receptor, the research team hypothesized that another enzyme must be at work in the pathway to remove the phosphate molecule from the receptor so it could be consumed by the body’s cells to ramp down the immune-system response to viruses.

Performing a screening for this putative enzyme, they identified protein tyrosine phosphatase 1 B (PTP1B) as a likely candidate. In a series of experiments, the researchers confirmed that blocking PTP1B decreased the removal of the interferon receptor. As a result, interferon signaling became enhanced. Using human cells infected with hepatitis C, the researchers found that adding a PTP1B inhibitor allowed smaller doses of interferon to be effective in keeping the virus from reproducing. They demonstrated a similar effect in human cells infected with vesicular stomatitis virus.

Aiding in their work was the fact that pharmaceutical companies have already designed multiple drugs that inhibit the activity of PTP1B but for a completely separate reason than the enzyme’s involvement in interferon signaling.

“PTP1B also works on the leptin receptor,” Fuchs said. “This is the pathway that regulates satiety, appetite and weight gain. So in the past 10 years there have been massive industrial and academic undertaking to develop PTP1B inhibitors to treat obesity and diabetes.”

To see how these PTP1B inhibitors would impact viral infections in a living organism, the researchers could not use mice because mice lack a portion of the receptor that PTP1B acts upon, and so blocking PTP1B does not impact interferon signaling in the same way as it does in humans and other mammals. Instead, they examined five cats that had been enrolled by their owners in the study. Each was suffering from chronic stomatitis, a condition that involves substantial inflammation in the mouth and makes it painful for the cats to eat and groom. The cats received a single injection of a PTP1B inhibitor. Two weeks later, all five showed noticeable reductions in redness and inflammation, providing clinical evidence that these drugs could be used to treat infection.

Fuchs said that what seemed like a drawback in the study — that it couldn’t be effectively modeled in mice — ended up being a benefit, as naturally occurring diseases in animals such as cat and dogs more closely mimic many human diseases.

Because interferon is known to suppress tumors and help multiple sclerosis patients, the results of this study give the researchers optimism that PTP1B could be a target for anti-cancer and anti-autoimmune disease therapies.

As a next step, they plan to test the PTP1B inhibitors in a model of feline immunodeficiency virus, or the cat version of AIDS, to see if its virus-fighting capabilities can have an effect against that infection.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Synthetic DNA Vaccine Against MERS Shows Promise
A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species.
Friday, August 21, 2015
Cell Aging Slowed by Putting Brakes on Noisy Transcription
Experiments in yeast hint at ways to extend life of some human cells.
Monday, August 03, 2015
Disrupting Cells’ ‘Powerhouses’ Can Lead to Tumor Growth
University of Pennsylvania researchers find that mitochondrial defects have a key role in a cells becoming cancerous.
Monday, July 13, 2015
New Tracking Method Yields Insights into Mitochondrial Dynamics
Scientists from the University of Pennsylvania have devised a powerful new technique that enables the tracking of every mitochondrion as it moves within a cell.
Thursday, July 02, 2015
Classification of Gene Mutations in Neuroblastoma
Penn Medicine and CHOP experts define riskier mutations in neuroblastoma, setting stage for clinical trial.
Tuesday, November 11, 2014
Potential Therapy for Myasthenia Gravis
Penn study demonstrates efficacy of potential therapy for autoimmune disorder of muscle weakness.
Wednesday, October 08, 2014
Center for Advanced Cellular Therapeutics to Rise on Penn Medicine Campus
New facility poised to accelerate the research and development of personalized cellular cancer therapies.
Friday, September 12, 2014
Gum Disease Bacteria Selectively Disarm Immune System, Penn Study Finds
New study shows that bacteria responsible for many cases of periodontitis cause dysbiosis.
Friday, June 13, 2014
Researchers Develop ‘Onion’ Vesicles for Drug Delivery
University of Pennsylvania researchers have shown that dendrimer-based vesicles self-assemble with concentric layers of membranes, much like an onion.
Wednesday, June 11, 2014
Cell Senescence, Aging Related to Epigenetic Changes
One way cells promote tumor suppression is through a process called senescence, an irreversible arrest of proliferation.
Monday, September 02, 2013
Penn Researchers Show Cocaine Addiction Resistance May Be Passed Down from Father to Son
Animal model reveals paternal cocaine use confers protection against rewarding effects of cocaine in male but not female offspring.
Tuesday, December 18, 2012
Tension on Gut Muscles Induces Cell Invasion in Zebrafish Intestine
Study finds this effect mimics cancer metastasis.
Wednesday, September 12, 2012
Pancreatic Cancer Can Run but Not Hide
Immune system tricked into helping cancer cells, but can be blocked, according to Penn study.
Wednesday, June 13, 2012
A Change of Heart: Penn Researchers Reprogram Brain Cells to Become Heart Cells
Researchers at the University of Pennsylvania demonstrate the direct conversion of a non-heart cell type into a heart cell by RNA transfer.
Thursday, July 14, 2011
A New Way to Make Reprogrammed Stem Cells
Penn study eliminates the use of transcription factors and increases efficiency 100-fold.
Wednesday, April 13, 2011
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!